PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1822615
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1822615
The global vial adaptors market was valued at USD 1 billion in 2024 and is projected to grow from USD 1.1 billion in 2025 to USD 1.9 billion by 2034, registering a CAGR of 6.5%, according to the latest report by Global Market Insights, Inc. The sector's momentum has been driven by market needs for safe drug sterile reconstitution and vaccinations, as well as a need to mitigate contamination risk in hospitals and clinical environments.
Vial adaptors help improve safety and efficiency by enabling 'needle-free' access when transferring and reconstituting injectable drugs, particularly in critical settings such as critical care, oncology, and vaccine administration.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $1 Billion |
Forecast Value | $1.9 Billion |
CAGR | 6.5% |
1. Increasing use of biologics and vaccines: Increasing numbers of biologic drugs and expanding vaccination programs have increased demand for safe and efficient reconstitution.
2. Infection prevention and safety issues: Vial adaptors provide needle-free, closed-system medication delivery, preventing needlestick accidents and microbial contamination.
3. Streamlining hospital and clinical workflow: These products make drug preparation easier, saving time and minimizing drug errors.
4. Regulatory push to close-system transfer devices (CSTDs): Global recommendations for using CSTDs for cancer and hazardous drug handling are accelerating vial adaptor adoption.
Major players like West Pharmaceutical Services, Thermo Fisher Scientific, Becton, Dickinson and Company, and ICU Medical hold a cumulative market share of 44.4%.
West is the leading domestic vial adaptor supplier with 21.2% market share in 2024.
Single-use vial adaptors were the market leader in 2024 due to their better infection control, regulatory compliance, and ease of use in hospitals and laboratory clinical settings. They are used in preference in chemotherapy, immunization, and critical care drug preparation.
A 20mm size offers universal applicability to therapy areas related to oncology, infectious diseases, and pediatrics.
In 2024, polycarbonate based vial adaptors lead the way, based upon durability, chemical resistance, and transparency permitting visual inspection during the transfer of the drug from the vial adapter to the syringe.
Hospitals continued to be the major End Uses of vial adaptors in 2024, since such facilities need aseptic, cost-effective drug administration systems to meet high patient loads, particularly in oncology and infectious disease departments.
North America continued to dominate the global market for vial adaptors with strong investments in healthcare infrastructure and advanced drug delivery systems. The usage of closed-system transfer devices (CSTDs) and promotion of infection prevention practices additionally enhance regional growth. North America dominated the world vial adaptors market in 2024, aided by increasing numbers of chronic diseases, high expenditure on healthcare, and sound hospital infrastructure. The region is also home to a number of prominent pharmaceutical and biotechnology companies, further driving the adoption of vial adaptors in sterile drug preparation. The US continues to be a dominant contributor because of growing vaccination efforts and extensive use of prefilled syringes and closed drug delivery systems.
Some of the major vial adaptors market players are B. Braun, Baxter International, Becton, Dickinson and Company, West Pharmaceutical Services, Yukon Medical, Thermo Fisher Scientific, ICU Medical, Helapet, Epic Medical, CODAN Medizinische Gerate, Miltenyi Biotec, EQUASHIELD, and VYGON.
Market leaders are placing bets on product innovation, collaborations, and regulatory clearances to remain competitive. An example of this is West Pharmaceutical Services, which continues to expand its portfolio of vial adaptors to facilitate safe reconstitution of biologics.;Becton, Dickinson and Company and Baxter International are incorporating vial adaptors into their infusion and prefilled syringe platforms to minimize contamination. Also, companies are spending money on sustainable materials/ adaptors of custom sizes to satisfy different hospital needs and drug formats.